By Sally Fallon and Mary G. Enig, PhD
Heart Protection Study (2002)
Carried out at Oxford University, this study received widespread press coverage; researchers claimed "massive benefits" from cholesterol-lowering, leading one commentator to predict that statin drugs were "the new aspirin." But as Dr. Ravnskov points out, the benefits were far from massive.
Those who took simvastatin had an 87.1 percent survival rate after five years compared to an 85.4 percent survival rate for the controls and these results were independent of the amount of cholesterol lowering.
The authors of the Heart Protection Study never published cumulative mortality data, even though they received many requests to do so and even though they received funding and carried out a study to look at cumulative data.
According to the authors, providing year-by-year mortality data would be an "inappropriate" way of publishing their study results.
PROSPER (2002)
PROSPER (Prospective Study of Pravastatin in the Elderly at Risk) studied the effect of pravastatin compared to placebo in two older populations of patients of which 56 percent were primary prevention cases (no past or symptomatic cardiovascular disease) and 44 percent were secondary prevention cases (past or symptomatic cardiovascular disease).
Pravastatin did not reduce total myocardial infarction or total stroke in the primary prevention population but did so in the secondary. However, measures of overall health impact in the combined populations, total mortality and total serious adverse events were unchanged by pravastatin as compared to the placebo and those in the treatment group had increased cancer. In other words: not one life saved.
J-LIT (2002)
Japanese Lipid Intervention Trial was a six-year study of 47,294 patients treated with the same dose of simvastatin. Patients were grouped by the amount of cholesterol lowering. Some patient had no reduction in LDL levels, some had a moderate fall in LDL and some had very large LDL reductions. The results: no correlation between the amount of LDL lowering and death rate at five years. Those with LDL cholesterol lower than 80 had a death rate of just over 3.5 at five years; those whose LDL was over 200 had a death rate of just over 3.5 at five years.
Meta-Analysis (2003)
In a meta-analysis of 44 trials involving almost 10,000 patients, the death rate was identical at 1 percent of patients in each of the three groups--those taking atorvastatin (Lipitor), those taking other statins and those taking nothing. Furthermore, 65 percent of those on treatment versus 45 percent of the controls experienced an adverse event. Researchers claimed that the incidence of adverse effects was the same in all three groups, but 3 percent of the atorvastatin-treated patients and 4 percent of those receiving other statins withdrew due to treatment-associated adverse events, compared with 1 percent of patients on the placebo.
Click to Read Part 12
Before starting any self treatment Dr. Grisanti recommends that you consider consulting with a doctor trained in functional medicine. Visit www.FunctionalMedicineUniversity.com to find doctors thoroughly trained in functional medicine
Functional medicine embraces the totality of the regulatory functions of the body. It encompasses all of the biophysical, biochemical, enzymatic, endocrine, immunological, and bioenergetic regulatory capacities.
Ronald Grisanti D.C., D.A.B.C.O., D.A.C.B.N., M.S.
